pandem
result
prolifer
clinic
trial
design
slow
spread
viru
caus
overwhelm
major
cardiovascular
cancer
patient
increas
risk
infect
accordingli
cardiovascular
cardiooncolog
commun
play
major
role
care
patient
mani
therapeut
agent
use
treat
patient
repurpos
treatment
influenza
drug
effect
ebola
patient
treatment
malaria
develop
decad
ago
unlik
familiar
cardiovascular
cardiooncolog
commun
provid
foundat
cardiovascular
cardiooncolog
physician
frontlin
provid
care
patient
better
understand
emerg
cardiovascular
epidemiolog
well
biolog
rational
clinic
trial
ongo
treatment
patient
pandem
result
prolifer
clinic
trial
design
slow
spread
sever
acut
respiratori
syndrom
coronaviru
viru
caus
therapi
rang
vaccin
repurpos
treatment
influenza
drug
effect
ebola
patient
treatment
malaria
develop
decad
ago
recogn
patient
underli
cardiovascular
risk
factor
cardiovascular
diseas
cancer
increas
risk
advers
outcom
recogn
vulner
popul
may
enrol
clinic
trial
present
critic
review
rational
differ
therapeut
current
employ
background
first
review
epidemiolog
follow
biolog
coronaviru
briefli
defin
complex
interplay
coronaviru
reninangiotensin
system
ra
directli
relev
care
major
patient
cardiovascular
diseas
cancer
receiv
drug
modul
system
final
review
mechan
action
multipl
therapi
current
studi
clinic
trial
given
breadth
inform
emerg
discuss
role
vaccin
current
impact
novel
coronaviru
sever
acut
respiratori
syndrom
coronaviru
unquantifi
number
confirm
case
death
global
pandem
increas
daili
http
http
coronavirusjhuedumaphtml
great
deal
still
remain
understood
initi
report
hospit
china
describ
infect
patient
provid
insight
diseas
multicent
retrospect
analysi
major
wuhan
resid
contact
wuhan
resid
although
neither
median
age
patient
year
interquartil
rang
iqr
femal
patient
sever
diseas
tend
older
tend
suffer
least
one
comorbid
compar
nonsever
diseas
retrospect
analys
patient
commonli
receiv
intraven
antibiot
oseltamivir
administ
system
steroid
oxygen
median
durat
hospit
day
interquartil
rang
day
howev
major
patient
remain
hospit
time
data
analys
clinic
cours
still
larg
remain
defin
epidemiolog
data
thu
far
suggest
patient
cardiovascular
risk
factor
includ
older
age
cardiovascular
diseas
cancer
suscept
infect
suffer
wors
clinic
outcom
also
directli
result
number
cardiovascular
complic
includ
fulmin
myocard
myocardi
injuri
heart
failur
arrhythmia
number
publish
case
report
clinic
suspect
myocard
markedli
elev
troponin
level
stsegment
elev
electrocardiogram
without
obstruct
coronari
diseas
presenc
sever
decreas
left
ventricular
systol
function
shock
cardiac
magnet
reson
imag
evid
diffus
myocardi
edema
gadolinium
enhanc
howev
anoth
isol
autopsi
report
patient
suffer
pneumonia
cardiac
arrest
obviou
histolog
chang
myocardium
observ
except
interstiti
mononuclear
inflammatori
infiltr
elev
troponin
level
also
observ
wors
clinic
outcom
retrospect
singlecent
analysi
hospit
patient
confirm
display
evid
cardiac
injuri
defin
elev
high
sensit
troponin
level
greater
th
percentil
upper
limit
confirm
cardiac
injuri
tend
older
median
age
versu
year
suffer
hypertens
versu
diabet
versu
coronari
heart
diseas
versu
heart
failur
versu
cancer
versu
patient
cardiovascular
risk
factor
diseas
increas
risk
suffer
wors
clinic
outcom
analysi
cohort
jinyintan
hospit
wuhan
hospit
patient
patient
hypertens
diabet
coronari
heart
diseas
increas
risk
mortal
upon
hospit
admiss
preval
hypertens
amongst
nonsurvivor
compar
survivor
versu
diabet
versu
cardiovascular
diseas
comorbid
also
like
present
patient
requir
intens
care
unit
admiss
contrast
estim
cumul
incid
case
wuhan
result
odd
infect
cancer
patient
estim
greater
ci
cancer
patient
infect
median
age
year
like
nonsmal
cell
lung
cancer
five
patient
treat
chemotherapi
immunotherapi
radiat
therapi
three
death
record
multicent
prospect
cohort
studi
case
hospit
case
histori
cancer
contrast
incid
cancer
chines
popul
per
peopl
amongst
infect
lung
cancer
common
patient
tend
older
compar
patient
without
cancer
patient
cancer
also
suffer
increas
risk
advers
event
tend
occur
earlier
includ
admiss
intens
care
unit
icu
need
invas
ventil
death
occur
patient
compar
patient
without
cancer
cancer
patient
recent
treat
chemotherapi
surgeri
also
like
suffer
clinic
sever
advers
event
coronavirus
cov
repres
larg
famili
hundr
envelop
singl
identif
sequenc
viru
respons
establish
novel
cov
share
sequenc
ident
two
batderiv
sarslik
cov
subsequ
shown
share
sequenc
homolog
sarscov
subsequ
renam
genom
coronavirus
encod
four
major
structur
protein
spike
protein
nucleocapsid
n
protein
membran
protein
envelop
e
protein
central
illustr
protein
respons
facilit
entri
cov
target
cell
compris
short
intracellular
tail
transmembran
anchor
larg
ectodomain
consist
receptor
bind
subunit
membranefus
subunit
given
far
known
respect
virolog
sarscov
given
two
coronavirus
appear
overlap
biolog
clinic
present
discuss
two
virus
togeth
emphasi
recent
studi
reveal
uniqu
aspect
biolog
aspect
review
viral
attach
entri
replic
sarscov
host
cell
discuss
integr
review
ongo
clinic
trial
target
differ
aspect
biolog
see
tabl
virus
enter
cell
bind
host
cellencod
protein
facilit
entri
viru
cell
well
allow
viru
surviv
replic
within
cell
virus
includ
certain
strain
cov
capabl
downmodul
entri
receptor
gain
access
cell
receptor
downmodul
strategi
broadli
use
mani
virus
escap
immun
system
well
establish
best
environ
viral
replic
spread
receptor
downmodul
may
also
disrupt
mani
natur
physiolog
function
host
cell
result
cell
death
lead
organ
level
dysfunct
entri
receptor
util
sarscov
angiotensinconvert
enzym
central
illustr
type
transmembran
carboxypeptidas
homolog
ace
ace
play
critic
role
activ
ra
process
angiotensin
angiotensin
angiotensin
ii
angiotensin
major
effector
peptid
ra
mediat
effect
select
interact
gprotein
coupl
angiotensin
ii
type
type
receptor
ace
howev
implic
entri
human
coronavirus
cell
highli
express
mouth
tongu
type
ii
alveolar
epitheli
cell
lung
also
abundantli
express
cardiovascular
endothelium
cardiac
myocyt
cardiac
fibroblast
well
epitheli
cell
kidney
testi
major
substrat
angiotensin
ii
cleav
ang
figur
function
associ
gproteincoupl
receptor
ma
receptor
ma
receptor
axi
regard
counterregulatori
arm
ra
oppos
effect
aceangiotensin
ii
although
precis
role
still
evalu
studi
shown
exert
protect
effect
pulmonari
cardiovascular
system
serv
oppos
deleteri
effect
ra
activ
protein
surfac
coronaviru
express
cell
surfac
receptor
bind
domain
protein
locat
subunit
undergo
conform
chang
bind
facilit
viral
attach
surfac
target
cell
bind
result
uptak
virion
endosom
central
illustr
viral
entri
cell
requir
prime
protein
serin
proteas
transmembran
proteas
serin
cleav
viral
protein
site
allow
fusion
viral
cellular
membran
protein
also
use
ph
sensit
endosom
proteas
cathepsin
b
l
prime
entri
cell
interestingli
bind
affin
ectodomain
higher
bind
sarscov
ectodomain
increas
sticki
capsid
protein
make
diseas
transmiss
like
might
explain
increas
persontoperson
transmiss
compar
sarscov
insofar
viral
protein
part
viru
interact
immun
system
may
serv
promis
target
vaccin
relev
discuss
convalesc
sera
sar
patient
shown
block
entri
entri
cultur
cell
albeit
less
effici
sarscov
howev
monoclon
antibodi
rais
receptor
bind
domain
protein
sarscov
bind
receptor
bind
domain
protein
suggest
sarsdirect
antibodi
cross
reactiv
protein
necessari
develop
effect
antibodi
although
ace
inhibitor
inhibit
hoffman
colleagu
demonstr
antibodi
prevent
entri
viral
vector
cell
line
express
protein
system
addit
layer
complex
understand
pathophysiolog
human
stem
complex
interact
cov
ra
figur
well
widespread
use
drug
interfer
ra
includ
angiotensin
convert
enzym
inhibitor
angiotensin
receptor
antagonist
angiotensin
receptor
neprilysin
inhibitor
drug
differ
effect
express
variou
compon
ra
differ
tissu
bed
briefli
discuss
import
interact
well
implic
treatment
patient
previou
studi
shown
sarscov
spike
protein
induc
express
cell
surfac
metalloenzym
term
adam
disintegrin
metalloproteinas
origin
describ
enzym
cleav
membran
bound
tumor
necrosi
factor
tnf
cell
surfac
allow
circul
solubl
form
shown
figur
activ
result
proteolyt
cleavag
refer
shed
cell
surfac
releas
catalyt
activ
solubl
ectodomain
circul
refer
solubl
decreas
level
cell
surfac
would
expect
result
decreas
level
ang
level
cytoprotect
correspond
increas
tissu
level
angiotensinii
proinflammatori
profibrot
import
regul
cell
surfac
demonstr
experiment
studi
wherein
administr
recombin
human
protein
genet
delet
receptor
administr
receptor
antagonist
shown
protect
acut
lung
injuri
model
observ
suggest
use
receptor
antagonist
may
benefici
patient
consist
losartan
current
test
random
doubleblind
placebo
control
studi
potenti
therapi
hospit
infect
patient
tabl
relev
discuss
ace
inhibitor
clinic
use
directli
affect
activ
biolog
signific
circul
known
note
retain
abil
bind
protein
sarscov
shown
prevent
entri
sarscov
cell
vitro
thu
may
act
decoy
receptor
prevent
bind
cell
surfac
human
recombin
solubl
shown
block
earli
stage
infect
cell
cultur
human
tissu
organoid
cultur
alreadi
undergon
safeti
toler
test
phase
ii
trial
healthi
volunt
time
write
test
clinic
patient
recognit
mani
patient
underli
medic
condit
treat
angiotensin
convert
enzym
ace
inhibitor
receptor
antagonist
coupl
knowledg
hypertens
diabet
treat
agent
increas
level
given
rise
concern
pharmacolog
upregul
ra
inhibitor
may
influenc
infect
patient
popul
alreadi
high
risk
sever
infect
howev
note
recent
review
topic
experiment
clinic
data
often
yield
conflict
result
respect
role
ace
inhibitor
receptor
antagonist
level
differ
pathophysiolog
context
suggest
effect
ra
inhibitor
complex
nuanc
assum
ra
inhibitor
assum
chang
level
heart
tissu
necessarili
reflect
chang
level
lung
portal
entri
given
limit
understand
respect
interact
ra
inhibitor
level
infect
human
believ
possibl
make
definit
statement
go
beyond
joint
statement
issu
march
heart
failur
societi
americath
american
colleg
cardiologyamerican
heart
associ
togeth
recommend
continu
raa
antagonist
patient
current
prescrib
agent
indic
agent
known
benefici
entri
envelop
virus
host
cell
occur
two
primari
mechan
one
direct
fusion
viral
membran
plasma
membran
host
cell
allow
viru
directli
deliv
genom
materi
cytosol
second
viru
hijack
cell
endocyt
machineri
bind
cell
surfac
receptor
trigger
endocytosi
virusreceptor
complex
central
illustr
endocyt
pathway
endocytos
virion
subject
activ
step
within
endosom
typic
mediat
acid
environ
endosom
result
fusion
viral
endosom
membran
allow
releas
viral
genom
cytosol
sever
virus
includ
hiv
sarscov
use
direct
membran
fusion
cell
surfac
endocytosi
enter
cell
note
recent
studi
suggest
bind
lead
endocytosi
receptorviru
complex
known
time
whether
also
capabl
directli
fuse
lipid
membran
cell
howev
base
similar
sarscov
behav
like
mode
entri
cell
similar
understand
differ
cell
entri
implic
develop
novel
therapeut
occur
direct
fusion
viral
membran
plasma
membran
host
cell
central
illustr
process
requir
process
viral
protein
near
cell
surfac
process
protein
expos
fusion
peptid
protein
insert
cell
membran
bring
envelop
viral
membran
closer
approxim
membran
host
cell
therebi
facilit
fusion
time
write
uptak
cell
shown
occur
endocytosi
complex
also
requir
prime
protein
known
whether
also
enter
though
direct
fusion
base
evid
link
activ
infect
small
molecul
serin
proteas
inhibitor
camostat
mesyl
may
also
attract
target
clinic
trial
tabl
camostat
mesyl
alreadi
shown
inhibit
replic
influenza
parainfluenza
virus
prevent
develop
pneumonia
viral
myocard
infect
mice
given
protein
activ
ph
depend
cystein
proteas
cathepsin
l
process
step
may
sensit
inhibit
drug
indirectli
inhibit
cathepsin
l
activ
interf
endosom
acidif
eg
bafilomycin
compound
directli
block
proteolyt
activ
cathepsin
l
also
suggest
antimalari
drug
chloroquin
hydroxychloroquin
might
exert
potent
antivir
effect
virtu
abil
increas
endosom
ph
insid
cell
chloroquin
hydroxychloroquin
rapidli
proton
concentr
endosom
posit
charg
chloroquin
increas
ph
endosom
prevent
cathepsininduc
prime
viral
protein
chloroquin
hydroxychloroquin
decreas
replic
cultur
cell
howev
hydroxychloroquin
potent
chloroquin
small
singlearm
studi
patient
confirm
treatment
hydroxychloroquin
associ
signific
differ
clear
viral
nasopharyng
carriag
within
day
compar
untreat
control
azithromycin
ad
hydroxychloroquin
significantli
effici
viru
elimin
howev
therapi
result
qt
prolong
caution
need
exercis
use
therapi
togeth
chloroquin
hydroxychloroquin
also
manifest
cardiotox
includ
cardiomyopathi
systol
diastol
atrioventricular
bundl
branch
block
detail
hydroxychloroqin
use
one
treatment
arm
world
health
organ
multin
solidarti
trial
also
current
investig
number
studi
tabl
interestingli
amiodaron
cation
amphiphil
shown
inhibit
ebola
viru
infect
vitro
target
cell
use
concentr
amiodaron
overlap
detect
sera
patient
treat
arrhythmia
amiodaron
main
metabolit
monodesethyl
amiodaron
mdea
shown
interfer
fusion
viral
envelop
endosom
membran
thu
block
viral
replic
amiodaron
also
shown
inhibit
sarscov
infect
spread
vitro
alter
late
compart
endocyt
pathway
act
transit
viru
endosom
genom
rna
sarscov
releas
cytoplasm
host
cell
positivestrand
viral
rna
translat
host
ribosom
one
larg
polypeptid
term
replicas
undergo
proteolyt
cleavag
yield
protein
requir
genom
replic
includ
viral
rnadepend
rna
polymeras
rdrp
viral
rdrp
gener
fulllength
antisens
negativestrand
viral
rna
templat
use
replic
posit
strand
viral
genom
rna
well
shorter
subgenom
neg
strand
rna
serv
templat
synthes
mrna
code
structur
protein
viru
includ
spike
membran
envelop
e
nucleocapsid
n
protein
translat
viral
mrna
occur
use
host
endoplasm
reticulum
viral
structur
protein
e
translat
endoplasm
reticulum
er
move
along
secretori
pathway
endoplasm
reticulumgolgi
intermedi
compart
viral
protein
becom
encapsul
bud
membran
contain
viral
structur
protein
follow
assembl
matur
virion
transport
cell
surfac
vesicl
releas
exocytosi
therapeut
viral
replic
number
antivir
drug
repurpos
treatment
partial
list
antivir
drug
discuss
antivir
activ
remdesivir
prodrug
metabol
activ
form
interfer
action
viral
rnadepend
rna
polymeras
result
decreas
viral
rna
product
known
howev
whether
remdesivir
termin
rna
chain
caus
mutat
remdesivir
effect
multipl
type
coronavirus
cell
cultur
mous
model
sar
howev
show
effect
patient
ebola
remdesivir
current
test
sever
clinic
trial
hospit
patient
pneumonia
tabl
remdesivir
also
one
four
treatment
arm
multin
solidar
trial
sponsor
multin
random
open
clinic
trial
evalu
safeti
compar
efficaci
hydroxychloroquin
remdesivir
combin
lopinavir
ritonavir
combin
lopinavir
ritonavir
plu
interferonbeta
solidar
use
adapt
design
allow
discontinu
drug
lack
effect
well
ad
new
drug
appear
promis
type
trial
design
offer
flexibl
effici
particularli
identif
earli
signal
relat
either
efficaci
toxic
maintain
studi
valid
rnadepend
rna
polymeras
like
remdesivir
prodrug
metabol
activ
form
favipiravirrtp
although
favipiravir
undergon
phase
iii
clinic
trial
treatment
influenza
yet
approv
fda
japan
grant
approv
favipiravir
treat
viral
strain
unrespons
current
antivir
preliminari
studi
favipiravir
shown
potent
antivir
activ
lopinavirritonavir
also
evalu
solidar
trial
number
addit
immunomodulatori
agent
also
current
evalu
includ
inhibitor
tocilizumab
glucocorticosteroid
tabl
given
cytokin
storm
syndrom
observ
subgroup
sever
increas
level
interleukin
il
addit
inflammatori
cytokin
one
metaanalysi
suggest
mean
level
ci
greater
patient
complic
compar
noncompl
tocilizumab
fda
approv
treatment
sever
cytokin
releas
syndrom
patient
treat
car
cell
therapi
also
approv
treatment
rheumatoid
arthriti
tocilizumab
monoclon
antibodi
bind
receptor
membran
bound
solubl
form
thu
inhibit
classic
downstream
signal
similarli
human
murin
chimer
monoclon
antibodi
siltuximab
although
fda
approv
treatment
cytokin
releas
syndrom
also
use
treatment
cytokin
releas
syndrom
also
studi
potenti
therapi
sever
infect
siltuximab
bind
directli
prevent
activ
immun
effector
cell
sarilumab
human
monoclon
antibodi
receptor
develop
treatment
rheumatoid
arthriti
also
evalu
sever
systemat
obtain
clinic
data
yet
support
benefit
use
steroid
report
suggest
possibl
detriment
delay
viral
clearanc
increas
risk
infect
mer
sar
although
role
steroid
area
activ
investig
tabl
pandem
present
innumer
challeng
health
care
organ
health
care
provid
given
vast
major
cardiovascular
patient
high
risk
infect
cardiovascular
cardiooncolog
commun
play
major
role
care
patient
forese
futur
commun
long
tradit
enrol
patient
clinic
trial
evalu
therapeut
agent
whose
mechan
action
familiar
clinic
equipois
enrol
patient
clinic
trial
come
month
lie
ahead
commun
ask
contribut
patient
clinic
trial
mechan
action
therapeut
agent
less
familiar
knowledg
base
requir
provid
care
acceler
dizzi
pace
tri
provid
foundat
cardiovascular
physician
frontlin
provid
care
patient
better
understand
emerg
cardiovascular
epidemiolog
well
biolog
rational
plethora
clinic
trial
either
design
current
recruit
patient
viru
genom
encod
four
major
structur
protein
spike
protein
nucleocapsid
n
protein
membran
protein
envelop
e
protein
protein
respons
facilit
entri
cov
target
cell
rout
employ
sarscov
includ
endocytosi
membran
fusion
rout
employ
via
endocytosi
whether
enter
cell
membran
fusion
known
bind
spike
protein
sarscov
lead
uptak
virion
endosom
viral
spike
protein
activ
ph
depend
cystein
proteas
cathepsin
l
activ
spike
protein
cathepsin
l
block
bafilomycin
ammonium
chlorid
indirectli
inhibit
activ
cathepsin
l
interf
endosom
acidif
chloroquin
hydroxychloroquin
weak
base
diffus
acid
cytoplasm
vesicl
endosom
lysosom
golgi
vesicl
therebi
increas
ph
inhibit
calpain
cathepsin
l
sarscov
also
directli
fuse
host
cell
membran
process
viru
spike
protein
type
ii
cell
membran
serin
proteas
camostat
mesyl
oral
activ
serin
proteas
inhibitor
major
effector
peptid
renin
angiotensin
system
angiotensin
ii
mediat
effect
select
interact
gprotein
coupl
angiotensin
ii
type
type
receptor
angiotensin
ii
degrad
ang
angiotensin
convert
enzym
ang
bind
ma
receptor
shown
ma
receptor
axi
oppos
effect
aceangiotensin
bind
spike
protein
induc
shed
activ
decreas
level
would
expect
result
decreas
level
ang
level
cytoprotect
correspond
increas
tissu
level
angiotensinii
proinflammatori
profibrot
type
ii
cell
membran
serin
proteas
activ
protein
allow
bind
abbrevi
ra
renin
angiotensin
system
uri
upper
respiratori
infect
sofa
sequenti
organ
failur
assess
